Skip to main content
main-content

Genitourinary cancers

News and opinion

04-01-2019 | Prostate cancer | News

Microsatellite instability linked to immunotherapy response in prostate cancer patients

The presence of the microsatellite instability-high/mismatch repair-deficient phenotype could help select advanced prostate cancer patients who are likely to derive durable clinical benefit from treatment with checkpoint inhibitors, say researchers.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.5801

02-01-2019 | Prostate cancer | News

Intermediate-term androgen suppression benefits higher risk prostate cancer

Patients treated with 18 months of androgen suppression plus radiotherapy have a significantly lower rate of prostate cancer-specific death at 10 years than those who receive 6 months of androgen suppression and radiotherapy, researchers report.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30757-5

18-12-2018 | Prostate cancer | News

Radical prostatectomy for localized disease extends life by nearly 3 years

Radical prostatectomy extends life by nearly 3 years compared with watchful waiting for men with clinically detected, localized prostate cancer, show long-term data from the SPCG-4 study.

Source:

N Engl J Med 2018; 379: 2319–2329

07-12-2018 | Risk factors | News

News in brief

Polycystic ovary syndrome associated with increased cancer risk

Women with polycystic ovary syndrome may have an increased likelihood for developing cancer, although the excess risk appears to be primarily restricted to those who are premenopausal, indicates a population-based study.

30-11-2018 | Bladder cancer | News

Hematuria linked to long-term risk for bladder, kidney cancer

Compared with the general population, adults with a hospital-based diagnosis of hematuria have a long-term increased risk for cancer, particularly bladder and kidney cancers, according to a Danish study.

Source:

JAMA Network Open 2018; 1: e184909

28-11-2018 | Prostate cancer | News

Multiparametric MRI does not render systematic prostate biopsy obsolete

Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30569-2
Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30607-7

22-11-2018 | Prostate cancer | News

Boosted surgical approach can match radiotherapy for prostate cancer survival

Treatment with radical prostatectomy plus adjuvant external beam radiotherapy and androgen deprivation therapy can offer equivalent survival outcomes to a nonsurgical approach in patients with high-risk prostate cancer, research shows.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4836

15-11-2018 | Prostate cancer | Podcast | Audio

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).

Click here for the accompanying news story.

15-11-2018 | Renal cell carcinoma | News

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30648-X
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30674-0

12-11-2018 | Bladder cancer | Highlight | News

Neoadjuvant pembrolizumab ‘worthwhile’ for some invasive bladder cancers

Neoadjuvant pembrolizumab therapy results in an “impressively high” pathologic complete response rate among patients with programmed cell death ligand 1-positive muscle-invasive bladder carcinoma, researchers say.

Source:

J Clin Oncol 2018; DOI: 10.1200/JCO.18.01148

09-11-2018 | Prostate cancer | News

NCRI 2018 in brief

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

06-11-2018 | Chemoprevention | News

NCRI 2018

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

Source:

NCRI 2018; Glasgow, UK

30-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | Video

Abiraterone alone likely suppresses testosterone sufficiently in mCRPC patients

Carsten Ohlmann discusses findings of the phase II SPARE trial that investigated forgoing LHRH therapy in metastatic prostate cancer patients receiving abiraterone acetate (5:16).

30-10-2018 | Renal cell carcinoma | ESMO 2018 | Video

Expert comment on the JAVELIN Renal 101 trial

ESMO expert Markus Joerger gives his views on the JAVELIN Renal 101 study pitting the combination of avelumab and axitinib against sunitinib in the first-line advanced RCC setting (1:48).

26-10-2018 | Renal cell carcinoma | ESMO 2018 | News

First-line avelumab–axitinib outperforms sunitinib in advanced RCC

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

Source:

ESMO 2018; Munich, Germany; 19–23 October

25-10-2018 | Castration-resistant prostate cancer | ESMO 2018 | News

News in brief

LHRH therapy may be SPAREd for abiraterone-treated mCRPC patients

Men with metastatic castration-resistant prostate cancer who are beginning treatment with abiraterone acetate plus prednisone may not need luteinizing hormone-releasing hormone therapy, suggest exploratory findings presented at the ESMO 2018 Congress in Munich, Germany.

14-09-2018 | Screening | News

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

Source:

BMJ 2018; 362: k3519, k3702

13-09-2018 | Castration-resistant prostate cancer | News

News in brief

SPARTAN: Adding apalutamide to ADT does not diminish nonmetastatic CRPC HRQoL

Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.

05-09-2018 | FDA | News

approvalsWatch

PD-L1 diagnostics approved for pembrolizumab, atezolizumab use in urothelial cancer

Read more on this US FDA update here

04-09-2018 | Bladder cancer | News

Neoadjuvant chemotherapy choice impacts bladder cancer outcome

Neoadjuvant chemotherapy with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin achieves better outcomes than gemcitabine plus cisplatin or carboplatin in patients with muscle-invasive bladder cancer, research shows.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.3542

image credits